US › Healthcare

Pluri Inc. (PLUR)

US · Healthcare · Biotechnology

$1.08-5.26%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$335,000

Revenue YoY

-15.8%

Net profit

$-5.9M

EPS

$-0.54

Net margin

-1,755.2%

Key statistics

Market cap

$15.5M

Forward P/E

3.6

P/B

306.56

Book value

$-2.13

EPS (TTM)

$-2.44

52-week high

$4.87

52-week low

$1.14

50-day MA

$1.64

200-day MA

$2.75

Beta

0.67

Analyst view

Analysts rate Pluri Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

42.52%

Institutions

20.68%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	0.16%
Morgan Stanley - Brokerage Accounts	0.03%
EverSource Wealth Advisors, LLC	0.02%
Citigroup Inc	0.01%
SIMA Wealth Partners, LLC	0.00%
Wells Fargo & Co	0.00%
Royal Bank of Canada	0.00%
JPMorgan Chase & Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pluri Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.